Onderzoeker
Sylvie Rottey
- Disciplines:Kankertherapie, Oncologie niet elders geclassificeerd, Kankerbiologie
Affiliaties
- Vakgroep Fundamentele en Toegepaste Medische Wetenschappen (Departement)
Lid
Vanaf1 okt 2018 → Heden - Vakgroep Farmacologie (Departement)
Lid
Vanaf1 okt 2008 → 30 sep 2018
Projecten
1 - 2 of 2
- Universeel, kosten-effectief open-source technologieplatform voor lichaamsvloeistof-biopsie met hoge gevoeligheid, gebaseerd op het profileren van het methyloom van circulerend DNA.Vanaf1 jan 2024 → HedenFinanciering: BOF - projecten
- Predictie van immuuntherapie response en toxiciteit in melanoom, nier- en longkanker door een transcriptoom gebaseerde immuun profilering.Vanaf1 nov 2021 → HedenFinanciering: FWO mandaten
Publicaties
31 - 40 van 103
- A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck : the RESGEX study(2021)
Auteurs: K. Klinghammer, J. Fayette, A. Kawecki, A. Dietz, P. Schafhausen, G. Folprecht, Sylvie Rottey, P. Debourdeau, J. Lavernia, A. Jacobs, et al.
- A randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (Suniforecast)(2020)Volume: 43
Auteurs: Marit Ahrens, Bernard Escudier, Ekaterini Boleti, Marc-Oliver Grimm, Marine Gross Goupir, Pilippe Barthelemy, Gwenaelle Gravis, Jens Bedekes, Philipp Ivanyi, Andrej Panic, et al.
Pagina's: 226 - 226 - Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).(2020)Volume: 38
Auteurs: Ben Tran, Lisa Horvath, Matthew Rettig, Karim Fizazi, Martijn P. Lolkema, Tanya B. Dorff, Richard Greil, Jean-Pascal H. Machiels, Karen A. Autio, Sylvie Rottey, et al.
Aantal pagina's: 1 - Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck : a case series of five patients(2020)
Auteurs: Karen Couvreur, Marlies De Bock, Randal D'Hondt, Philippe Deron, Fréderic Duprez, Sylvie Rottey
Pagina's: 362 - 369 - Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer(2020)Volume: 8
Auteurs: Tanya Dorff, Matthew Rettig, Jean-Pascal Machiels, Martijn Lolkema, Karen Autio, Richard Greil, Sylvie Rottey, Nabil Adra, Mark Salvati, Shirley Poon, et al.
Pagina's: A207 - A208 - A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors(2020)Volume: 80
Auteurs: Juanita S. Lopez, Ross Camidge, Marco Iafolla, Sylvie Rottey, Martin Schuler, Matthew Hellmann, Ani Balmanoukian, Luc Dirix, Michael Gordon, Ryan Sullivan, et al.
Aantal pagina's: 1 - On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors(2020)
Auteurs: Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, Sylvie Rottey, Simon A. J. Rule, David Cunningham, Frederic Peyrade, Christophe Fruchart, Hendrik-Tobias Arkenau, Isabelle Genvresse, et al.
Pagina's: 468 - 478 - 'In-house' data on the outside : a mobile health approach(2020)
Auteurs: Qinlei Huang, Tami Crumley, Christina Walters, Liesbeth Cluckers, Ingeborg Heirman, Radha Railkar, Gaurav Bhatia, Matthew Cantor, Christopher Benko, Elena S Izmailova, et al.
Pagina's: 948 - 956 - Safety, tolerability, and potential clinical activity of a glucocorticoid-induced TNF receptor-related protein agonist alone or in combination with nivolumab for patients with advanced solid tumors : a phase 1/2a dose-escalation and cohort-expansion clinical trial(2020)
Auteurs: Kimberley M Heinhuis, Matteo Carlino, Markus Joerger, Massimo Di Nicola, Tarek Meniawy, Sylvie Rottey, Victor Moreno, Anas Gazzah, Jean-Pierre Delord, Luis Paz-Ares, et al.
Pagina's: 100 - 107 - A phase 1 study of mTORC1/2 inhibitor BI 860585 as a single agent or with exemestane or paclitaxel in patients with advanced solid tumors(2020)
Auteurs: Filippo de Braud, Jean-Pascal H. Machiels, Daniela Boggiani, Sylvie Rottey, Matteo Duca, Marie Laruelle, Stefania Salvagni, Silvia Damian, Lore Lapeire, Marcello Tiseo, et al.